

## **Supplemental material for:**

### **New *Lmna* knock-in mice provide a molecular mechanism for the “segmental aging” in Hutchinson-Gilford progeria syndrome**

**Hea-Jin Jung *et al.***

#### **SUPPLEMENTAL METHODS**

##### **Luciferase reporter assay**

Luciferase reporter vectors (pmirGLO, Promega) with full-length prelamins A 3' UTR, mutant versions of prelamins A's 3' UTR with 3-nucleotide mutations (CAA>ACC, CAA>del) (Supplementary Material, Fig. S1A), or lamin C's 3' UTR were reported previously (1). A luciferase reporter vector with the “ACCCT” mutation was generated by site-directed mutagenesis with primer 5'–AGCAGGCCTGAAGACCCTGAAAAATTTATC–3' and a complementary reverse primer. HeLa and U-87 MG cells were cotransfected with the luciferase vectors along with either a miR-9 expression vector or an empty vector (2). After 24 h, the cells were lysed with Passive Lysis Buffer (Promega) and analyzed for firefly- and Renilla-luciferase activities with the Dual-Luciferase Reporter Assay System (Promega) and a Synergy 2 luminometer (Biotek).

##### **Myeloid cell studies**

Bone marrow cells were harvested from the femur and tibia by flushing with PBS. Red blood cells were removed by incubation in red blood cell lysis buffer (0.15 M NH<sub>4</sub>Cl, 10

mM KHCO<sub>3</sub>, 0.1 mM EDTA) at 37° C for 3 min. Peritoneal cells were collected by peritoneal lavage with PBS and resident macrophages were isolated by cell adherence in DMEM medium containing 10% FBS at 37°C for 1 h. After washing with PBS twice, adherent cells were collected with cell scrapers.

For protein analysis, cells were lysed in urea buffer and processed as described in the *Materials and Methods*. microRNA levels were measured by qRT-PCR as described (1). Total RNA was isolated with an RNeasy kit (Qiagen) and reverse-transcribed with miRCURY LNA Universal cDNA synthesis kit II (Exiqon). qPCR reactions were performed on a 7900 Fast Real-Time PCR system (Applied Biosystems) with the ExiLENT SYBR Green PCR Master Mix and LNA PCR primers (Exiqon).

### **Fluorescence *in situ* hybridization**


One-month-old mice were perfused with 4% paraformaldehyde (PFA) and tissues were cryoprotected in 20% sucrose overnight at 4° C. Tissues were then embedded in Optimum Cutting Temperature compound (Sakura Finetek) and sectioned (10 μm). *In situ* hybridization was performed with the miRCURY LNA microRNA ISH Optimization kit (Exiqon). Slides were treated with proteinase K (2 mg/ml) for 10 min at 37° C and then incubated in 3% hydrogen peroxidase in PBS to block endogenous peroxidase activity. After dehydration in 70%, 96%, and 99.9% ethanol, the slides were incubated with digoxigenin-labeled probes (40 nM) in 1× microRNA ISH buffer (Exiqon) for 1 h at 55° C and washed with 5×, 1×, and 0.2× SSC buffers (5 min each) at 55° C. Slides were then incubated with polymerized horseradish peroxidase (POD)-conjugated anti-digoxigenin sheep IgG (Roche). Antibody binding was detected with the TSA Plus Systems (PerkinElmer).




## **REFERENCES**

- 1 Jung, H.J., Coffinier, C., Choe, Y., Beigneux, A.P., Davies, B.S., Yang, S.H., Barnes, R.H., 2nd, Hong, J., Sun, T., Pleasure, S.J. *et al.* (2012) Regulation of prelamin A but not lamin C by miR-9, a brain-specific microRNA. *Proc. Natl. Acad. Sci. U. S. A.*, **109**, E423-431.
- 2 Delaloy, C., Liu, L., Lee, J.A., Su, H., Shen, F., Yang, G.Y., Young, W.L., Ivey, K.N. and Gao, F.B. (2010) MicroRNA-9 coordinates proliferation and migration of human embryonic stem cell-derived neural progenitors. *Cell Stem Cell*, **6**, 323-335.
- 3 Coffinier, C., Jung, H.J., Nobumori, C., Chang, S., Tu, Y., Barnes, R.H., 2nd, Yoshinaga, Y., de Jong, P.J., Vergnes, L., Reue, K. *et al.* (2011) Deficiencies in lamin B1 and lamin B2 cause neurodevelopmental defects and distinct nuclear shape abnormalities in neurons. *Mol. Biol. Cell*, **22**, 4683-4693.
- 4 Jung, H.J., Nobumori, C., Goulbourne, C.N., Tu, Y., Lee, J.M., Tatar, A., Wu, D., Yoshinaga, Y., de Jong, P.J., Coffinier, C. *et al.* (2013) Farnesylation of lamin B1 is important for retention of nuclear chromatin during neuronal migration. *Proc. Natl. Acad. Sci. U. S. A.*, **110**, E1923-1932.


**SUPPLEMENTAL FIGURES**




**Figure S1.** The “ACCCT mutation” in the seed-binding sequence of the miR-9 binding site in prelamina A’s 3’ UTR abolishes the effects of miR-9 on prelamina A expression. (A) Mutation of the predicted miR-9 binding site in prelamina A’s 3’ UTR. The location of the CCAAAG => ACCCTG mutation is indicated by blue font; the location of the three-nucleotide mutations (CAA>ACC and CAA>del), which were described previously (1), are underlined in red. (B and C) Luciferase assays in HeLa cells (B) and U-87 MG cells (C) that had been transfected with an empty vector (control) or a miR-9 expression vector (miR-9) along with luciferase reporter vectors in which the miR-9 seed-binding sequence (CCAAAG) in prelamina A’s 3’ UTR was mutated. From left to right: A (full), wild-type 3’ UTR of prelamina A; CAA>ACC, substitution of nucleotides CAA in prelamina A’s 3’ UTR with ACC; CAA>del, deletion of the CAA in prelamina A’s 3’ UTR; ACCCT, substitution of the five nucleotides in prelamina A’s 3’ UTR (CCAAA) with ACCCT; C (full), wild-type 3’ UTR of lamin C (1). Firefly luciferase activity levels were normalized to Renilla luciferase activity levels and compared to those in cells transfected with the luciferase vector containing the wild-type 3’ UTR of lamin C (set at 1.0). Values represent mean  $\pm$  SD. The ACCCT mutation abolished the ability of miR-9 to reduce luciferase expression in both HeLa cells and U-87 MG cells. Consistent with earlier studies in HeLa cells (1), mutating (or deleting) three nucleotides (CAA) in the predicted miR-9 binding site also blocked the inhibition by miR-9. In these cell culture studies, the levels of miR-9 expression in the transfected cells were only ~10% of the levels normally observed in the cerebral cortex of wild-type mice (1). (–),  $p > 0.05$ .




**Figure S2.** Western blot analysis of lamin B1 and lamin B2 expression in the cerebral cortex, cerebellum, heart, liver, and kidney from *Lmna*<sup>+/+</sup> (+/+), *Lmna*<sup>PLAO/PLAO</sup> (PLAO/PLAO), *Lmna*<sup>PLAO-UTR/PLAO-UTR</sup> (UTR/UTR), and *Lmna*<sup>PLAO-5NT/PLAO-5NT</sup> (5NT/5NT) mice. The same blots shown in Fig. 2A were re-probed with antibodies against lamin B1 and lamin B2. (See Fig. 2B–D for quantification of lamin B1 and lamin B2 signals.)



**Figure S3.** Western blot analysis of tissue extracts from *Lmna*<sup>PLAO/+</sup> (PLAO/+), *Lmna*<sup>PLAO-UTR/+</sup> (UTR/+), and *Lmna*<sup>PLAO-5NT/+</sup> (5NT/+) mice with antibodies against lamin A/C and actin. (A–D) Western blots of tissue extracts from 1-month-old mice. (E–G) Quantification of lamin A and lamin C levels relative to actin measured in panels A–D. Values represent mean ± SD. \**p* < 0.05; \*\**p* < 0.005; \*\*\**p* < 0.0005.




**Figure S4.** Lamin A and miR-9 expression in myeloid cells. (A) Western blot analysis of protein extracts of bone marrow myeloid cells (BM) and adherent peritoneal macrophages (PE) from *Lmna*<sup>PLAO/+</sup> (PLAO/+), *Lmna*<sup>PLAO-5NT/+</sup> (5NT/+), and wild-type (+/+) littermate mice. (B) qRT-PCR analysis of the levels of miR-9 or miR-129 in myeloid cells. Data was normalized to U6 snRNA. Values represent mean  $\pm$  SD from four 1-month-old mice and four 7.5-8-month-old mice.




**Figure S5.** Immunofluorescence microscopy of the striatum/cortex, cerebellum, hippocampus/thalamus, and midbrain from wild-type (WT), *Lmna*<sup>PLAO/+</sup> (PLAO/+), *Lmna*<sup>PLAO-5NT/+</sup> (5NT/+), and *Lmna*<sup>PLAO-UTR/+</sup> (UTR/+) mice stained for lamin A (red or white) and lamin C (green). Scale bar, 100 μm. CTX, cerebral cortex; STR, striatum; CC, corpus callosum; ML, molecular layer; AV, arbor vitae; GR, granular layer; IP, interposed nucleus; SG, strata granulosum; SP, strata pyramidale; TH, thalamus; IC, inferior colliculus.






**Figure S6.** Expression of miR-9 and prelamin A transcripts in the striatum. (A) Fluorescence *in situ* hybridization on brain sections from 1-month-old *Lmna*<sup>PLAO-UTR/+</sup> mice with a miR-9 probe or a scrambled control probe. CTX, cerebral cortex; STR, striatum. Scale bar, 100  $\mu$ m. (B) Quantitative RT-PCR analysis of prelamin A transcript levels and total *Lmna* transcript levels in the striatum and the cerebral cortex of *Lmna*<sup>+/+</sup> ( $n = 2$ ) and *Lmna*<sup>PLAO-UTR/PLAO-UTR</sup> mice ( $n = 2$ ). Transcript levels were normalized to cyclophilin A and compared to levels in wild-type mice (set at 1.0).




**Figure S7.** Immunofluorescence microscopy of the hippocampus or the corpus callosum from *Lmna*<sup>PLAO/+</sup> (PLAO/+), *Lmna*<sup>PLAO-5NT/+</sup> (5NT/+) and *Lmna*<sup>PLAO-UTR/+</sup> (UTR/+) mice stained with antibodies against lamin A (red), lamin C (cyan in Panel A; magenta in Panel B), and either NeuN (green) in Panel A or GFAP (green) in Panel B. White arrowheads, lamin A–negative/lamin C–positive cells; white arrows, lamin A–negative/lamin C–negative cells; yellow arrows, lamin A–positive/lamin C–positive cells. Scale bars: (A) 40 μm; (B) 20 μm.






**Figure S8.** *Lmna*<sup>PLAO-5NT/PLAO-5NT</sup> and *Lmna*<sup>PLAO-UTR/PLAO-UTR</sup> mice are free of pathology. (A and B) Photographs of 1-month-old *Lmna*<sup>PLAO-5NT/PLAO-5NT</sup> (5NT/5NT), *Lmna*<sup>PLAO-UTR/PLAO-UTR</sup> (UTR/UTR), and wild-type (+/+) littermate mice. Scale bar, 1 cm. (C–E) Hematoxylin and eosin (H&E)-stained sections of the cerebral cortex (C), hippocampus (D), and cerebellum (E) from 1-month-old *Lmna*<sup>PLAO/PLAO</sup> (PLAO or PLAO/PLAO), *Lmna*<sup>PLAO-5NT/PLAO-5NT</sup> (5NT or 5NT/5NT), *Lmna*<sup>PLAO-UTR/PLAO-UTR</sup> (UTR or UTR/UTR), and wild-type (+/+) littermate mice. Scale bars: panel C, 100 μm; panel D, 200 μm; panel E, 100 μm.




**Figure S9.** Increased lamin A expression in the brain does not affect localization of other nuclear membrane proteins. The cerebral cortex from *Lmna*<sup>PLAO-5NT/PLAO-5NT</sup> (5NT/5NT), *Lmna*<sup>PLAO-UTR/PLAO-UTR</sup> (UTR/UTR), and wild-type (WT) littermate mice was stained with antibodies against emerlin (green), lamin A (red), and Nup98 (magenta) in (A) and LAP2β (green) and SUN1 (magenta) in (B). Scale bar, 20 μm.





**Figure S10.** Absence of neuropathology in the brains of older *Lmna*<sup>PLAO-5NT/PLAO-5NT</sup> and *Lmna*<sup>PLAO-UTR/PLAO-UTR</sup> mice. (A–C) H&E–stained sections of the cerebral cortex (A), hippocampus (B), and cerebellum (C) from 6.5-month-old *Lmna*<sup>PLAO-5NT/PLAO-5NT</sup> (5NT/5NT) mice and 9.5-month-old *Lmna*<sup>PLAO-UTR/PLAO-UTR</sup> (UTR/UTR) mice along with wild-type (+/+) littermate mice. Scale bars: panel A, 100  $\mu$ m; panel B, 500  $\mu$ m; panel C, 50  $\mu$ m. (D) Immunofluorescence microscopy of the cerebral cortex from 6.5-month-old *Lmna*<sup>PLAO-5NT/PLAO-5NT</sup> (5NT/5NT) and 9.5-month-old *Lmna*<sup>PLAO-UTR/PLAO-UTR</sup> (UTR/UTR) mice stained with antibodies against NeuN (magenta), active caspase 3 (green), and lamin A (red). Scale bar, 100  $\mu$ m. (E) High-magnification images of the cerebellum from 6.5-month-old *Lmna*<sup>PLAO-5NT/PLAO-5NT</sup> (5NT/5NT) mice, 9.5-month-old *Lmna*<sup>PLAO-UTR/PLAO-UTR</sup> (UTR/UTR) mice, and wild-type (+/+) littermate mice stained with active caspase 3 (green) and lamin A (red). Scale bar, 50  $\mu$ m.



**Figure S11.** *Lmna*<sup>PLAO-UTR/PLAO-UTR</sup> mice are indistinguishable from wild-type mice by SHIRPA behavioral screens (A) and by rotarod tests (B). Forebrain-specific *Lmnb1* knockout mice (*Emx1-Cre Lmnb1*<sup>fl/fl</sup>) (3), knock-in mice expressing nonfarnesylated lamin B2 (*Lmnb2*<sup>CS/CS</sup>) (4), and wild-type littermates were included as controls. No statistically significant differences were observed between wild-type mice and *Lmna*<sup>PLAO-UTR/PLAO-UTR</sup> mice. See Supplementary Material, Table S2 for the description of each test.

		WT	PLAO	5NT	UTR	Lamin C
<b>Cerebellum</b>	Granule cells	-	-	-	-	+++
	Purkinje cells	-	-	-	++	++++
	Arbor vitae	-	++	++++	++++	+++
	Interposed nucleus	-	-	-	++	++++
	Molecular layer	-	-	-	-	++
<b>Midbrain</b>	Inferior colliculus	-	-	+	+++	++++
<b>Cerebrum</b>	Cerebral cortex	+	++	+++	++++	++++
	Corpus callosum	+	++	++++	++++	+++
	Striatum	-	-	-	+	++
<b>Hippocampus</b>	Strata granulosum	-	-	-	++	+++
	Strata pyramidale	+	+	++	++++	++++
	Thalamus	-	-	-	+++	++++
<b>Olfactory bulb</b>	Granule cells	-	-	-	++	+++
	Glomerular layer	-	-	-	++	+++
	Mitral cells	-	-	-	+	++++

**Table S1.** Lamin A expression in different regions of the brain from *Lmna*<sup>PLAO-5NT/+</sup> and *Lmna*<sup>PLAO-UTR/+</sup> mice, as judged by immunohistochemistry. +, ++, +++, and ++++ indicate the intensity of lamin A staining by immunohistochemistry [from + (very weak) to ++++ (very strong)]; - denotes undetectable lamin A expression (Fig. S4). Blue, regions of the brain in which lamin A expression was increased in *Lmna*<sup>PLAO/+</sup> mice compared with *Lmna*<sup>+/+</sup> mice; yellow, regions of the brain in which lamin A expression was increased in *Lmna*<sup>PLAO-5NT/+</sup> mice compared with *Lmna*<sup>PLAO/+</sup> mice; green, regions of the brain in which lamin A expression was increased in *Lmna*<sup>PLAO-UTR/+</sup> mice compared with *Lmna*<sup>PLAO-5NT/+</sup> mice; grey, regions of the brain in which lamin A expression changed very little, even in *Lmna*<sup>PLAO-UTR/+</sup> mice.

View Jar	Body Position	0-Completely flat	1-Lying on Side	2-Lying Prone	3-Sitting or standing	4-Rearing on hind legs	5-Repeated vertical leaping
	Spontaneous Activity	0-None, resting	1-Casual groom, slow movement	2-Vigorous groom, moderate movement	3-Vigorous, rapid/dart movement	4-Extremely vigorous, rapid/dart movement	
	Respiration Rate	0-Gasping, irregular	1-Slow, shallow	2-Normal	3-Hyperventilation		
	Tremor	0-None	1-Mild	2-Marked			
	Urination	Count					
Arena	Defecation	Count					
	Transfer Arousal	1-Prolonged freeze, slight movement	2-Extended freeze, moderate movement	3-Brief freeze, active movement	4-Barely freeze, immediate movement	5-No freeze, immediate movement	6-Extremely excited (manic)
	Locomotor Activity	Squares entered within 30s					
	Palpebral Closure	0-Eyes wide open	1-Eyes 1/2 closed	2-Eyes closed			
	Piloerection	0-None	1-Coat stood on end				
	Startle Response	0-None	1-Preyer reflex-flick of pinnae	2-Jump <1cm	3-Jump >1cm		
	Gait	0-Normal	1-Fluid but abnormal	2-Limited movement only	3-Incapacity		
	Pelvic Elevation	0-Markedly flattened	1-Barely touches	2-Normal (3mm)	3-Elevated (>3mm)		
Held by Tail	Tail Elevation	0-Drugging	1-Horizontally Extended	2-Elevated			
	Touch Escape	0-No response	1-Mild (escape to firm stroke)	2-Moderate (rapid response to light stroke)	3-Escape response to approach		
	Positional Passivity	0-Struggles when held by tail	1-Struggles when held by scruff	2-Struggles when laid supine	3-Struggles when held by hind legs	4-No struggle	
	Trunk Curl	0-present	1-absent				
	Limb grasping	0-present	1-absent				
	Abnormal Behavior	0-present	1-absent				
	Visual Placing	0-None	1-Upon nose contact	2-Upon vibrassa contact	3-Before contact-18mm	4-Early extension-25mm	
Reflex	Whisker Brush	0-No response	1-Response to vigorous brush	2-Response to mild brushing	3-Response to initial touch		
	Whisker placement	0-None	1-Upon head contact	2-Upon vibrassa contact	3-Before vibrassa contact		
	Grip Strength	0-None	1-Slight grip, semi-effective	2-Moderate grip, effective	3-Active grip, effective	4-Unusually effective	
	Body Tone	0-Flaccid, no return to normal	1-Slight resistance	2-Extreme resistance, boardlike			
	Pinna reflex	0-None	1-Active reaction, brisk flick	2-Hyperactive, repetitive flick			
	Corneal reflex	0-None	1-Active single eye blink	2-Multiple eye blink			
	Toe Pinch	0-None	1-Slight withdrawal	2-Moderate withdrawal, not brisk	3-Brisk, rapid withdrawal	4-Rapid extension/flexion	
Supine Restraint	Wire Manoeuvre	0-Active grip with hindlegs	1-Difficulty grasp with hindlegs	2-Unable to grasp with hindlegs	3-Unable to lift hindlegs, falls	4-Fall immediately	
	Heart Rate	0-Slow, bradycardia	1-Normal	2-Fast, tachycardia			
	Limb Tone	0-No resistance	1-Slight resistance	2-Moderate resistance	3-Marked resistance	4-Extreme resistance	
	Abdominal Tone	0-Flaccid, no return to normal	1-Slight resistance	2-Extreme resistance, boardlike			
	Salivation	0-None	1-Slight margin of submax	2-Wet zone entire sub-max			
	Provoked Biting	0-Absent	1-Present				
	Penlight Vision	0-No response	1-Pupil dilation	2-Rapid blinking			
Other	Righting Reflex	0-No impairment	1-Lands on side	2-Lands on back	3-Fails to right when on back		
	Contact Righting Reflex	0-Absent	1-Present				
	Negative Geotaxis	0-Turns and climbs on grid	1-Turns but then freezes	2-Moves, but fails to turn	3-Does not move w/in 30s	4-Falls off	
	Fear	0-None	1-Freeze with transfer arousal				
	Irritability	0-None	1-Struggle with supine restraint				
	Aggression	0-None	1-Provoked biting or attack				
Other	Vocalization	0-None	1-Provoked during handling				

**Table S2.** List of tests performed during the SHIRPA primary screen and the scoring criteria for each test.



**A**

<b>A</b>	5'-TCGAATCCGCATTGACAGCCTCT-3'
<b>B</b>	5'-AAAGTTCAGGCCCTTCTGGT-3'
<b>C</b>	5'-AGTACAACCTGCGCTCACGC-3'
<b>D</b>	5'-TGATGCTGCAGTTCTGGGAGC-3'
<b>E</b>	5'-ACAACCTAGTCACCCGCTCCTA-3'
<b>F</b>	5'-ATGTGTCTGCCCTGAAAAC-3'
<b>NeoF</b>	5'-TGCTCCTGCCGAGAAAGTAT-3'
<b>NeoR</b>	5'-AAGCGAAGGAGCAAAGCTGCTA-3'

**B**

Antigen	Antibody	Species	Company	Western Blot	IHC
Actin	Polyclonal	Goat	Santa Cruz (sc-1616)	1:1000	
Caspase-3	Monoclonal	Rabbit	Cell Signaling (9664)		1:100
Ctip2	Monoclonal	Rat	Abcam (ab18465)		1:500
Cux1	Polyclonal	Rabbit	Santa Cruz (sc-13024)		1:100
GFAP	Monoclonal	Mouse	BD Pharmingen (556327)		1:800
Lamin A	Monoclonal	Mouse	Millipore (MAB3540)		1:400
Lamin A/C	Polyclonal	Goat	Santa Cruz (sc-6215)	1:400	
Lamin B1	Polyclonal	Goat	Santa Cruz (sc-6217)	1:400	1:400
Lamin B2	Monoclonal	Mouse	Invitrogen (33-2100)	1:400	
Lamin C	Polyclonal	Rabbit	Lifespan Biosciences (LS-B2972)		1:200
NeuN	Monoclonal	Mouse	Millipore (MAB377)		1:500
Olig2	Polyclonal	Rabbit	Millipore (AB9610)		1:500
LAP2 $\beta$	Monoclonal	Mouse	BD Biosciences (611000)		1:400
Emerin	Monoclonal	Mouse	Novocastra (NCL-EMERIN)		1:200
SUN1	Polyclonal	Rabbit	Abcam (ab74758)		1:800
Nup98	Monoclonal	Rat	Abcam (ab50610)		1:250

**Table S3.** List of primers and primary antibodies. (A) Sequences of the primers used in 5' and 3' long-range PCR reactions and genotyping PCR reactions for the *Lmna*<sup>PLAO-5NT</sup> and *Lmna*<sup>PLAO-UTR</sup> alleles. (B) List of primary antibodies used in this study.